Edwards Lifesciences (EW) Current Leases (2014 - 2026)

Edwards Lifesciences' Current Leases history runs 9 years deep, the most recent figure standing at $24.3 million for Q1 2026.

• On a quarterly basis, Current Leases rose 2.53% year-over-year to $24.3 million in Q1 2026; TTM through Mar 2026 was $24.3 million, a 2.53% increase from a year earlier, with the FY2025 full-year figure at $24.5 million, up 4.7% from the prior year.
• Current Leases declined to $24.3 million in Q1 2026 per EW's latest filing, from $24.5 million in the prior quarter.
• Across five years, Current Leases topped out at $26.8 million in Q3 2025 and bottomed at $21.5 million in Q2 2024.
• The 5-year median for Current Leases is $24.3 million (2023), against an average of $24.2 million.
• Across the five-year window, Current Leases slipped 11.52% in 2024 and climbed 20.47% in 2025, its largest moves.
• Year by year, Current Leases stood at $25.5 million in 2022, then decreased by 10.2% to $22.9 million in 2023, then grew by 2.18% to $23.4 million in 2024, then increased by 4.7% to $24.5 million in 2025, then declined by 0.82% to $24.3 million in 2026.
• Per Business Quant, the three latest EW Current Leases figures stand at $24.3 million (Q1 2026), $24.5 million (Q4 2025), and $26.8 million (Q3 2025).